# Fresenius Medical Care AG: Form 20-F for the period ended Dec 31, 2016

- Company: [Fresenius Medical Care AG](/companies/fms.md) (CIK 1333141)
- Form: 20-F
- Filed: 2017-02-22
- Accepted by EDGAR: Feb 22, 2017, 11:20 ET
- Period: 2016-12-31
- Accession: 0001047469-17-000816
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1333141/000104746917000816/a2230893z20-f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1333141/000104746917000816/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 12 months, 2016-01-01 to 2016-12-31 | $12.13bn | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2016-01-01 to 2016-12-31 | $5.78bn | us-gaap:GrossProfit |
| Research and development | 12 months, 2016-01-01 to 2016-12-31 | $162.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2016-01-01 to 2016-12-31 | $3.04bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2016-01-01 to 2016-12-31 | $2.64bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2016-01-01 to 2016-12-31 | $452.2m | us-gaap:InterestExpense |
| Income tax | 12 months, 2016-01-01 to 2016-12-31 | $683.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2016-01-01 to 2016-12-31 | $1.24bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2016-01-01 to 2016-12-31 | $4.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2016-01-01 to 2016-12-31 | $4.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2016-01-01 to 2016-12-31 | 306,257,744 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2016-01-01 to 2016-12-31 | $2.14bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2016-01-01 to 2016-12-31 | $1.03bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2016-01-01 to 2016-12-31 | −$277.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2016-12-31 | $747.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $7.31bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $26.93bn | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $5.04bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-12-31 | $14.24bn | us-gaap:Liabilities |
| Long-term debt | at 2016-12-31 | $7.20bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-12-31 | $605.7m | us-gaap:DebtCurrent |
| Short-term borrowings | at 2016-12-31 | $602.5m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2016-12-31 | $10.81bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2016-12-31 | 306,221,840 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1333141/000104746917000816/a2230893z20-f.htm

Filed Feb 22, 2017.
Source: SEC EDGAR, the filing index for accession 0001047469-17-000816. Last ingested by Listed: Nov 10, 2026, 00:27 ET. No prices; not investment advice.